Yoshimi Muta on Muck Rack

Yoshimi Muta

As seen in: Nature, Associated Press: Press Releases, Business Wire, KMJF-TV (Norfolk, NE), KNEN-TV (Norfolk, NE), KGMT-AM (Fairbury, NE), The Bakersfield Californian, BioSpace, KFOL-TV - HTV10, Financial Content and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yoshimi

Contact Yoshimi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes

|
By Yukihiro Wada, Kazuo Kobayashi, Shunichiro Tsukamoto, Daiji Kawanami, Daisuke Suzuki, Daisuke Tsuriya, Hiromichi Wakui, Keizo Kanasaki, Yoshimi Muta, Kouichi Tamura, Yasuo Takeuchi, Masao Toyoda, Takaya Matsushita, Masuo Saburi
| Nature
Abstract Combination therapy with a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) is increasingly used to prevent cardiovascular events. Our previous study demonstrated the renal benefits of this combination therapy. Both drug classes exert pleiotropic effects on metabolic factors, such as obesity and hypertension; however, the impact of this combination therapy on blood pressure (BP) has not been fully evaluated.
Open in Who Shared Issue with article?

Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference

|
By Yoshimi Muta, Ryota Usui, Katsuhiko Hagi, Wataru Nihei
| BioSpace
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, today announces that five presentations in relation to the potential of Imeglimin, marketed under the brand name TWYMEEG® in Japan, will be made at the 85th Scientific...
Open in Who Shared View Duplicates (35) Issue with article?
See all 29 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Yoshimi

Contact Yoshimi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified